These findings indicate that selective inhibition of LO enzymes, such as LOXL1, either alone or in combination with LOXL2 inhibition, might be a potential therapeutic strategy for targeting fibrosis in IPF. Here, LOXL2 is linked to idiopathic pulmonary fibrosis.